Novartis (NVS) Biosimilar Of MabThera Approved In The EU
Zacks Investment Research | Jun 19, 2017 04:56AM ET
Novartis AG (NYSE:NVS) announced that its generic arm, Sandoz, has received European Commission (EC) approval for Rixathon, a biosimilar version of Roche’s (OTC:RHHBY) MabThera in Europe.
The biosimilar version has been approved for all the indications of the branded drug. Rixathon is approved for non-Hodgkin's lymphoma (follicular lymphoma and diffuse large B-cell lymphoma) and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.
We note that Sandoz is a global leader in biosimilars. With the approval of Rixathon, Sandoz now has four biosimilar drugs approved in Europe along with a deep pipeline. Sandoz plans to obtain the approval for four more biosimilars of major oncology and immunology biologics by 2020.
Last month, the European Medicines Agency (EMA) accepted the company’s Marketing Authorization Applications for biosimilar versions of Humira (adalimumab) and Remicade (infliximab) for review. The generic unit had generated $10.1 billion sales in 2016.
Last week, the FDA accepted Sandoz’s Abbreviated New Drug Application (ANDA) for a generic version of GlaxoSmithKline’s (NYSE:GSK) asthma drug, Advair Diskus.
We remind investors that Sandoz gaining additional expertise in the development of orally inhaled medicines through its 2010 acquisition of Oriel Therapeutics, Inc. Upon approval, the generic drug will treat asthma in patients aged four years and older, as well as provide maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Earlier in 2017, Mylan (NASDAQ:MYL) received a complete response letter from the FDA regarding its ANDA for Advair Diskus.
Hence, we expect investors to remain focused on Sandoz’s ANDA approval. A potential approval will give Sandoz the edge over Mylan and boost its portfolio.
Novartis has outperformed the Zacks classified industry in the last six months. The stock has rallied 12.6% compared with the Large Cap Pharmaceuticals industry’s gain of 11.4%.
Going forward, we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis. However, the company faces stiff generic competition for key drugs like Gleevec.
Zacks Rank
Get The News You Want
Novartis currently carries a Zacks Rank #3 (Hold).
You can see .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.